The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.
The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline.
复制标题
DOI：
10.1186/scrt361
复制
发表时间：
2013
影响因子：
7.5
通讯作者：
Tagle DA
中科院分区：
文献类型：
--
作者：
Sutherland ML;Fabre KM;Tagle DA
美国国立卫生研究院与美国食品和药物管理局以及国防高级研究计划局合作，加速人体微生理系统 (MPS) 的开发，以解决药物开发临床前阶段新分子实体的预测毒性评估和功效分析所面临的挑战。使用人类 MPS 可以为预测新分子实体在临床试验中的功效提供更好的模型。人们还预计，通过使用 MPS 或人体器官芯片，在药物开发过程的早期预测药物毒性的改进将减少从市场上撤回新疗法的需要，并最大限度地减少或消除因不明药物毒性而导致的死亡。
The National Institutes of Health has partnered with the US Food and Drug Administration and the Defense Advanced Research Projects Agency to accelerate the development of human microphysiological systems (MPS) that address challenges faced in predictive toxicity assessment and efficacy analysis of new molecular entities during the preclinical phase of drug development. Use of human MPS could provide better models for predicting the efficacy of new molecular entities in clinical trials. It is also anticipated that improvements in predicting drug toxicities early in the drug development process through the use of MPS or human organs-on-a-chip will decrease the need to withdraw new therapies from the market and minimize or eliminate deaths due to unidentified drug toxicities.
登录
查看更多内容
影响因子：
17.1
作者：
Collins, Francis S.
通讯作者：
Collins, Francis S.
影响因子：
120.7
作者：
Lasser, KE;Allen, PD;Bor, DH
通讯作者：
Bor, DH
影响因子：
3.8
作者：
Vassallo, JD;Hicks, SM;Lehman-McKeeman, LD
通讯作者：
Lehman-McKeeman, LD
影响因子：
5.1
作者：
Lauer, Birthe;Tuschl, Gregor;Mueller, Stefan O.
通讯作者：
Mueller, Stefan O.
影响因子：
3
作者：
Volpe, DA;Tomaszewski, JE;Grieshaber, CK
通讯作者：
Grieshaber, CK